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Theuseofantiretroviral therapyhas reducedmortality and increased thequalityof lifeofHIV-1-infectedpeople,
particularly inmore developed countrieswhere access to treatment ismorewidespread.However,morbidities
continue, which include HIV-1-associated neurocognitive disorders (HAND). Subtle cognitive abnormalities
and low-level viral replication underlie disease. The balance between robust antiviral adaptive immunity,
neuronal homeostatic mechanisms, and neuroprotective factors on one hand and toxicities afforded by dys-
regulated immune activities on the other govern disease. New insights into the pathobiological processes
for neuroimmune-linked disease and ways to modulate such activities for therapeutic gain are discussed.
Better understanding of the complexities of immune regulation during HAND can improve diagnosis and
disease outcomes but is also relevant for the pathogenesis of a broad range of neurodegenerative disorders.Introduction
Human immunodeficiency virus type I (HIV-1) is a lentivirus that
infects CD4+ T cells, dendritic cells, monocytes, and macro-
phages. A progressive immunodeficiency resulting from the
destruction of CD4+ T cells and immune dysfunction result in
the acquired immunodeficiency syndrome (AIDS), which leads
inevitably to a broad range of opportunistic infections (OI) and
malignancies. It continues to ravage the world; the latest
UNAIDS/WHO statistics (July 2008, numbers as of the end of
2007) indicate that there are 33 million people living with HIV/
AIDS, two-thirds of whom live in Sub-Saharan Africa, with the
majority living in resource-poor regions (http://www.who.int/
hiv/pub/epidemiology/pubfacts/en/).
While the immune system disorders are the focus of much
study, HIV-1 infection has significant effects on the nervous
system, as the virus both infects and affects the brain (Yadav
and Collman, 2009). Prior to the advent of antiretroviral therapy
(ART), OIs were a common complication of advanced HIV-1
infection associated with advanced immunosuppression and
reduced CD4+ T cell counts. These included infection of the
central nervous system (CNS) with heterologous viruses (cyto-
megalovirus, herpes, and JC viruses), mycobacteria (tubercu-
losis and atypical mycobacterial infections), fungi (crypto-
coccus), protozoa (toxoplasmosis), and malignancies including
lymphoid cancers linked to Epstein-Barr virus. These still con-
tinue with ART, albeit reduced (Langford et al., 2003). However,
functional and pathological abnormalities of theCNS occur in the
absence of OIs and have been linked directly or indirectly to
HIV-1 itself and the host responses to it (Boisse et al., 2008).
This continues to be the most common cause of neurologic
disease in the setting of progressive HIV infection, although
shifts in pathogenesis from florid HIV replication to more diverse
mechanisms have recently been noted (Everall et al., 2009).
Herein, we specifically review recent findings for how HIV can
damage the nervous system and how it may be treated, with
a focus on what has been found on how virus interacts betweenthe nervous and immune systems. As with many issues in
biomedical science, the bulk of our knowledge exists from those
in regions rich in medical and research infrastructure, and our
review reflects these. We note that the problems caused by
HIV for the brain disproportionally affect those in resource-
poor areas, and considerable efforts are being mobilized to
address this (Robertson and Hall, 2007).
The HIV-associated neurocognitive disorder (HAND) com-
prises a broad range of neurological abnormalities, including
asymptomatic neurocognitive impairment, HIV-associated mild
cognitive motor disorder, and the most severe disease, HIV-1-
associated dementia (or HAD) (Antinori et al., 2007). Severe
dementia now affects less than 7% of infected people during
the latter stages of disease. Due to the increasing longevity of
HIV-1-infected individuals, the incidence of HAD as well as the
other cognitive and motor abnormalities associated with HIV-1
infection have declined, although the prevalence of HAND has
increased (Antinori et al., 2007; Dore et al., 2003; Sacktor,
2002; Woods et al., 2009). The most severe cognitive, motor,
and behavioral impairments are now supplanted by milder,
less profound cognitive impairment that can have significant
negative ramifications on employment, medication adherence,
and other activities of daily living (Grant, 2008).
HADwas first described nearly two and a half decades ago and
has been associated with an encephalitis characterized by
enhanced CNS viral replication, formation of macrophage-
derived multinucleated giant cells, astrogliosis, microgliosis,
neuronal loss, andmyelin pallor. There have beenmany excellent
reviews of neuroAIDS, and readers are referred to these for an in-
depth reference (Ellis et al., 2007; Gonzalez-Scarano andMartin-
Garcia, 2005; Kaul et al., 2005; McArthur et al., 2005). In the
current era of widespread use of ART, HIV-linked CNS disease
is associated with more subtle neuropathological changes and
appears linked to synaptodendritic damage (Ellis et al., 2007).
HIV-1-related brain pathology such as encephalitis is now an
infrequent finding (Everall et al., 2009). The neuropathogenesisNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 133
Neuron
Reviewof HIV-1 infection is most likely a metabolic encephalopathy trig-
gered by viral infection and immune activation of brain mononu-
clear phagocytes (MPs; blood-derived perivascular macro-
phages and microglia) (Zheng and Gendelman, 1997).
However, other causes and pathologies are still being sought.
HIV-1 infection is now a chronic condition and can exhibit
interactions with other neurodegenerative disorders. Older age
has indeed been identified as a risk factor for HAD (Valcour
et al., 2004), and in HIV-1-infected individuals on ART, extrapy-
ramidal motor signs are linked to age (Valcour et al., 2008).
Epidemiological trends now suggest a risk of concomitant
neurodegenerative disease such as increased risks for devel-
oping Alzheimer’s disease (Ikezu, 2009). Notably, increased
b-amyloid is found in the brain in HIV-1 infection, and patients
with HAND show increased aggregation of b-amyloid within
neurons (Achim et al., 2009). The complexities of disease patho-
biology for HAND are becoming even broader. Coexisting condi-
tions, such as drug abuse (Bell et al., 1998; Rippeth et al., 2004)
and infection with hepatitis C virus (Clifford et al., 2009; Letendre
et al., 2007), may play significant roles in HAND. These further
serve to complicate disease diagnosis and treatment strategies
andwarrant a re-evaluation of the importance of disease biology.
MP Immunity, Viral Infection, and Immune Activation
HIV-1 infectionof theCNS isknown to initiatedisease, unlikeother
neurodegenerative disorderswhere the cause and effect relation-
ships between innate microglial inflammation and neuronal injury
are unclear. HIV-1 enters thebrain early after infection. Themeans
to regulate MP inflammatory responses dictate the tempo and
progression of cognitive dysfunction. Much is now known in this
regard. In neuroAIDS, MPs are recruited to the brain. Themecha-
nism for HIV-1 infection of the CNS is commonly described as
a ‘‘TrojanHorse’’ in studiesof lentiviral pathogenesis (Gendelman,
et al., 1985, 1986; Haase, 1986). Herein, virus resides in a
restricted state within monocytes or following differentiation into
macrophagesandbuds intoendocyticcompartmentswith limited
cell surface expression of viral proteins. This allows the cell, in
part, to escape immune surveillance (Gendelman et al., 1994),
paralleling the ancient mythological Trojan horse that Odysseus
devised, allowing the Greeks to secretly enter the city of Troy.
For lentiviruses, this is the virus’s strategy of entering the brain
and overcoming the restrictions imposed by a seemingly imper-
meable blood-brain barrier (BBB). Monocytes attracted into the
brain by a chemokine gradient penetrate the BBB and differen-
tiate into macrophages. This infiltration of peripheral cells then
allows viral dissemination within the brain.
Monocytes-Macrophages and the BBB
Diapedesis of monocytes across the BBB during HIV-1 infection
is a hallmark of neuroAIDS and occurs as a consequence of
ongoing brain MP activation. Secretory factors released from
immune-competent HIV-1-infected macrophages and microglia
affect the pathobiologic activities that underlie the cascading
immune events leading to the development of HAD/HIV-1
encephalitis (HIVE). MP infection leads to glial activation in the
brain. HIV-1 and proinflammatory factors first affect the integrity
of the BBB. For example, HIV-1 signals through signal trans-
ducers and activators of transcription 1 in human brain micro-134 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.vascular endothelial cells in the BBB, inducing interleukin-6
(IL-6) secretion, which speeds monocyte migration (Chaudhuri
et al., 2008). This is perpetuated through monocyte chemoat-
tractant protein 1 (MCP-1) secreted by both MP and astrocytes.
Indeed, MCP-1 is a potent chemoattractant for macrophages
and monocytes, further orchestrating MP brain infiltration
(Peng et al., 2008b). Ongoing viral replication as well as the viral
proteins themselves induce MCP-1 secretion (Eugenin et al.,
2006). MP can also affect the microvascular proteome and
vice versa to elicit proinflammatory changes required for trans-
endothelial migration (Ricardo-Dukelow et al., 2007). Thus, inter-
play between viral and cellular factors initiates disease. OnceMP
gain entry into the brain, the proinflammatory environment trig-
gered by ongoing viral infection leads to further MP activation
and secretion of proinflammatory cytokines, chemokines, and
arachidonic acid metabolites that serve to exacerbate BBB
dysfunction and the neurodegenerative process.
MP and Neurodegenerative Responses
HowMPs can affect neurodegeneration is certainly complex and
can occur through a number ofmechanisms, each of which is not
mutually exclusive. For example, HIV-1gp120 is shed from the
surface of progeny virus and can elicit neurotoxicity (Cornblath
and Hoke, 2006) through the production of cytokines from astro-
cytes and microglia. HIV-1gp120 overexpression in transgenic
mice elicits neural damage, which correlates with gp120 protein
concentrations (Okamoto et al., 2007) and is dependent on acti-
vation of c-Jun N-terminal kinase (JNK) and p42 extracellular-
regulated kinase. HIV-1gp120 is also responsible for signaling
the release of a broad range of proinflammatory factors from
macrophages, in part through phosphatidylinositol-3 kinase
and mitogen-activated protein kinase signaling (Cheung et al.,
2008; Lee et al., 2005).
While HIV-1gp120 induces cytokine and chemokine secretion
and facilitates disease progression, this is just a portion of the
many mechanisms of neuroinflammatory activities seen in
disease. Indeed, viral infection itself can lead to MP activation
and thesecretionofabroad rangeofneurotoxic factors.Cytokines
and chemokines released as a consequence further enhance MP
activation during HIV-1 infection, resulting in local neuronal
dysfunction/death as well as additional monocyte-macrophage
recruitment across the BBB (Brabers and Nottet, 2006; Persidsky
et al., 2006). For example, TNF-a increases the permeability of the
BBB and increases adhesion molecules on the epithelial cells
required for cell transmigration. TNF-a induces an inflammatory
cascade resulting in macrophage cytoskeleton remodeling and
further increasing cytokine secretion (Kadiu et al., 2007). IL-1b
shares neurotoxic properties with TNF-a, including NMDA
receptor-mediated neurotoxicity (Brabers and Nottet, 2006; Strij-
bos and Rothwell, 1995). In the context of HIV-1 infection in the
CNS, TNF-a and IL-1b are primarily considered toxic (Brabers
andNottet, 2006) and, interestingly, affect IL-8 secretion by astro-
cyteswithin the CNS (Saas et al., 2002). Although IL-8 is a chemo-
kine involved in neutrophil chemoattraction, it is increased in the
CSF in HAD (Zheng et al., 2008). These are among many conjoint
innate immune responses that are operative in disease.
Recent studies have raised questions for whether HIV CNS
disease is a result of compartmentalized nervous system
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system. Here virus-infected monocyte-macrophages enter the
brain early, spread infection within neighboring glial cells, then
rapidly establishment viral latency. In this scenario, evolution to
high-level viral replication would occur late in disease where
immune surveillance mechanisms are broken. Alternatively,
peripheral infection would lead to altered monocyte-macro-
phage function and concomitant immune activation causing
subsequent egress of cells to the brain. Phenotypic changes
could occur between resident microglia and thosemacrophages
accumulating from blood from bone marrow origins. In this later
scenario, unique populations of CD16+CD163+ perivascular
brain macrophages would have an altered phenotype that would
directly affect disease processes (Fischer-Smith et al., 2008).
M1 and M2 MP Phenotypes and Disease Regulation
One hypothesis espoused for HAND is the control of the MP
phenotype. Viral infection and immune activation drive M1
responses, while antiviral responses (drugs and immune surveil-
lance mechanisms) drive M2. Certainly, cytokine and chemokine
secretion by MP are in large part controlled by the MP polariza-
tion state, either as an M1 or M2 phenotype (Benoit et al., 2008).
M1 polarized macrophages are activated through classical path-
ways and secrete proinflammatory cytokines such as TNF-a, IL-
1b, and interferon-g (IFN-g). M2 polarizedmacrophages are acti-
vated through an alternative pathway by IL-4 and IL-13, resulting
in the secretion of anti-inflammatory cytokines such as IL-10 and
IFN-b. M1 polarization, which is relatively short-lived, affects the
levels of HIV-1 replication and neurotoxicity, while M2 polariza-
tion results in long-term decreased viral production and neural
homeostasis despite no change in proviral DNA and viral protein
levels (Cassol et al., 2009) (Figure 1). During disease, MPs are re-
cruited into the brain and, depending on the neural environment,
can affect the activation state of perivascular cells. These blood-
bornemacrophages are amajor source of virus spread aswell as
neurotoxic mediators. The ongoing inflammatory environment in
affected brain tissue dictates the tempo of disease and affects
both macrophage and microglial innate immune responses
that regulate neuronal function (Figure 1). Successful control of
the macrophage and microglial phenotype remains a target in
the development of new therapies that affect neuroinflamma-
tion-induced neurodegenerative activities.
Glial Crosstalk
While abundant studies support the role ofmacrophages andmi-
croglia in HIV-1-induced CNS damage, other glia such as astro-
cytes likely play a crucial role. HIV-1-exposed astrocytes upregu-
late complement C3 in an effort to clear the infectious agent
(Speth et al., 2002). This upregulation of complement C3 was
demonstrated in proteomic studies of cerebrospinal fluid (CSF)
inHIV-1andSIV (Pendyalaet al., 2009;Rozeketal., 2007). Intrigu-
ingly, the classic complement cascade (including C3) mediates
neuronal synaptic destruction during development and, when
activated later, may contribute to neurodegeneration (Stevens
et al., 2007). HIV-1 binding to astrocytes and/or the local produc-
tion of MP-derived proinflammatory factors can induce robust
proinflammatory responses (Li et al., 2007). Astrocytes secrete
chemokine ligand-10 (CXCL10), a potent chemoattractant, whichacts synergistically in the presence of proinflammatory cytokines
and HIV-1-recruiting immune cells (Williams et al., 2009).
Astrocytes are also known to contribute to glutamate excito-
toxicity during HIV-1 infection (comprehensively reviewed by
Erdmann et al., 2006). Glutamate causes oxidative stress in glial
cells, which can negatively affect neurons. HIV-1 also has been
found to induce astrocyte expression of matrix metallopeptidase
9, which is known to contribute to degradation of the BBB
(Ju et al., 2009).
Astrocytes also produce high levels of stromal cell-derived
factor-1a (SDF-1a, CXCL12), induced by IL-1b. Evidence has
been provided for the effects of SDF-1 during HAND to be
both beneficial and detrimental; however, the true role is still
unclear (Peng et al., 2006). Finally, astrocyte secretion of low
levels of TNF-a and IL-1b by HIVE patients provide further evi-
dence for the contribution of proinflammatory astrocytes to the
toxic inflammatory environment (Xing et al., 2009). Further explo-
ration of the role of astrocytes during HIV-1 infection is vital to
understanding the mechanism(s) that leads to the development
of HAND in HIV-1 infected individuals.
Considerable evidence now exists for cooperation among glial
cells in affecting neurotoxic activities. Cocultivation of astrocytes
andmicroglia has yielded great insight into glial cell communica-
tion as it occurs during HIV-1 infection. Astrocytes can affect the
microglial phenotype during HIV-1 infection by altering expres-
sion of microglia structural proteins, chemoattractants, levels
of viral replication, and neurotoxins (Wang et al., 2008a). HIV-
1-infected astrocytes also accelerate MP cell death and induce
oxidative stress (Wang et al., 2008b). The ability of astrocytes
to regulate HIV-1-infected microglial neurotoxicity serves to
define the tempo of HAND (Figure 2).
Adaptive Immunity, Viral Infection, and Disease Control
Cytotoxic T Cells
Along with the innate response, there is good evidence of an
adaptive response to HIV-1 (and in the monkey SIV) in the brain.
Within weeks following SIV inoculation, a significant increase in
the number of CD8+ T cells is present within the brains of infected
animals (Marcondes et al., 2001). These cells have distinct
patterns of T cell receptor clonal rearrangements relative to those
found in the lymphoid tissues, indicating regional specificity in the
adaptive cellular response (Marcondes et al., 2007). Such brain-
infiltrating cells have been shown to beSIV-specificCTL function-
ally, and analyseswith SIV-specific tetramer reagents confirm the
specific CTL presence and enrichment in the CNS (Marcondes
etal., 2007). InSIVencephalitis, theseCD8+Tcellsareoften found
associated with infected macrophages (Kim et al., 2004), further
indicating their specificity and activity. Interestingly, combined
antiretroviral treatment, at least in the short-term, does not lower
the number of these cells in the brain (Marcondes et al., 2009).
CD8+ T cells are found in the brains of patients with HIVE
(Petito et al., 2003, 2006). Furthermore, similar to the studies in
monkeys, these cells can be found in the brains before the devel-
opment of disease (McCrossan et al., 2006). During the course of
infection, increased CD8+ T cell activation is found in the CSF
(Neuenburg et al., 2005), including HIV-1-specific CTL (Jassoy
et al., 1993; Sadagopal et al., 2008). CTL response to HIV-1 in
the CNS and elsewhere is critical in the body’s protection fromNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 135
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A schematic of the cascade of neuropathologic events during progressive HIV-1 infection of the CNS. Activatedmonocytes are drawn to the brain by chemokines.
CNS infection serves to activate astrocytes and resident microglia, resulting in the spread of infection to neighboring cells with concomitant neuroinflammation.
Uponactivation,microglia polarize toeither anM1orM2phenotype, leading to aneurotoxic or neurotrophicmicroglial phenotypeduringHIV-1 infectionof theCNS.the virus. In a distinctly specialized organ such as the brain, CTL
activity may also have harmful effects, such as bystander
damage to neurons or support cells. CTLs accumulate and
persist in the brain, likely throughout the now lengthened period
of infection. As with the innate response, these adaptive CTLs
may be double-edged swords—needed for viral control but
capable of leading to brain injury.
Regulatory T Cells and Neuroprotection
Natural regulatory T cells (Treg) have been identified as key
contributors to the control of self-tolerance (reviewed by Saka-
guchi, 2000). More recently, their role in immune suppression
has been investigated in many neurodegenerative disorders,136 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.such as Parkinson’s disease (PD) (Reynolds et al., 2007), amyo-
trophic lateral sclerosis (ALS) (Banerjee et al., 2008), and stroke
(Liesz et al., 2009). HIV-1-infected individuals have increased
Treg populations (Cao et al., 2009; Terzieva et al., 2009), and
increases in Treg are seen even as other T cell populations are
decreasing during later stages of infection (Rallon et al., 2009).
In contrast, effector T cells (Teff) can exacerbate immune activa-
tion and perpetuate the progression of HIV-1 infections, while
Treg have aprofoundanti-inflammatory response, decreasing as-
trogliosis and microglial inflammation leading to neuroprotection
(Liu et al., 2009) (Figure 2). The balance between Treg and Teff
responses can affect the tempo and progression of HIV-1 neuro-
pathogenesis. This, however, is not limited to neuroAIDS.
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Within the infected brain, both proinflammatory (Teff, CTL, M1 microglia) and protective (M2 microglia, Treg) aspects of immunity are evident (adapted from
Huang et al., 2009). When the inflammatory environment becomes dominant, disease is manifest.Neuron 64, October 15, 2009 ª2009 Elsevier Inc. 137
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capable of slowing the progression of PD through modulation of
the microglial phenotype (Reynolds et al., 2009a, 2009b). In ALS,
Treg populations are decreased (Mantovani et al., 2009). Also, in
animal models of ALS, transferring activated Treg to ALS animals
delaysneurological symptomonsetand lossofmotor functionwith
extended survival (Banerjee et al., 2008). The benefits of Treg in
CNS HIV-1 infection, whereby a tolerance response is induced
instead of activating the immune system in response to infection
and neurodegeneration, has recently been reviewed (Huang
et al., 2009). Prophylactic induction of Treg is thus becoming
recognized as an important potential therapeutic approach for
neurodegenerative diseases. Recent studies support the notion
that controlling the immune system to regulate the inflammatory
response is essential to decreasing neural damage caused by
secretion of proinflammatory cytokines and that are exacerbated
toTeff responses.Thebalance isnoteasilyseen,asTeff responses
serve to control viral infection. Thus, the balance between control
of inflammation and viral replication is critical in control of HIV-1
neuroimmunity and neurotoxicity (Figure 2).
Immune Reconstitution Inflammatory Syndrome
IRIS is a condition observed in some immunosuppressed people
with advanced HIV infection during the time the affected
patient’s immune system begins to recover after ART and
responds to prior OIs. This is manifest by a robust inflammatory
response that paradoxically speeds disease. Most patients will
recover without treatment. However, when manifest within the
CNS, a common CD8+ T cell lymphocyte infiltration can cause
significant morbidity and sometimes mortality (Gray et al.,
2005; Venkataramana et al., 2006). CNSmanifestations highlight
the role of prior infections and how a newly competent immune
response can affect disease in the brain.
Mechanisms of Neuronal Demise
Apoptosis has long been thought to represent the end result of
neuronal damage in neuroAIDS. Recently, it has been found that
there is a strong interdependent relationship between apoptosis
and autophagy mechanism (Maiuri et al., 2007). Autophagy and
the ubiquitin-proteasome system (UPS) are responsible for the
clearance of intracellular proteins. While apoptosis is a synchro-
nized process leading to cell death, autophagy is now largely
considered a mechanism to protect from toxicity in stress condi-
tions.Strikingly, inhibitionofautophagycanalso induceapoptosis
(Boya et al., 2005). In cells such as neurons, removal of abnormal
cellular components, such as aggregated proteins or damage
organelles, is necessary to prevent cellular damage that can
trigger apoptosis. In vivo, inhibition of autophagy in neurons leads
to neurodegeneration (Hara et al., 2006; Komatsu et al., 2006).
Studies using the SIV-infected monkey model have revealed
inhibition of neuronal autophagy in the presence of encephalitis
(Alirezaei et al., 2008a, 2008b). Supernatants from SIV-infected
microglia inhibit autophagy in primary neuronal cultures and
induce their death; furthermore, accumulation of p62/sequesto-
some 1, a protein cleared by autophagy, is present in neurons in
the brains of infected monkeys as well as HIV-infected people.
Recent studies have confirmed findings of decreased autophagy
in the brains of HIV-1-infected people and feline immunodefi-138 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.ciency virus infected cats, as well as in vitro studies with human
neurons (Zhu et al., 2009).
Other reports indicate that alterations in the UPS also occur in
HIVE (Gelman and Nguyen, 2009; Gelman and Schuenke, 2004).
In cells such as neurons, autophagy is especially important
where the UPS apparatus is insufficient; thus, the processes
related to intracellular clearance in neurons may be an Achilles’
heel in the untoward effects of HIV-1 on neurons. It is also inter-
esting that lithium, which increases autophagy by inhibiting
inositol monophosphatase (Sarkar et al., 2005), has been shown
to have efficacy in preclinical models of neuroAIDS (Dou et al.,
2005). Lithium is now being clinically tested in those with neuro-
AIDS (Letendre et al., 2006; Schifitto et al., 2009), potentially link-
ing some of the newer adjunctive therapies being tested in neu-
roAIDS (see below) with autophagy.
Therapeutic Milestones
Antiretroviral Drugs and NeuroAIDS
Multimodality antiretroviral treatment has emerged as the main-
stay for effective treatment of HIV-1-infected patients, reducing
bothmorbidities anddiseasemortality. ForCNSHIV-1 infections,
ART-naive, HAD patients with significant cognitive dysfunction
show dramatic improvement in neurologic function following
ART initiation (Gendelman et al., 1998), which is coincident with
and thought to be a function of lowered viral loads. Following
therapy, levels of neurotoxins in plasma and CSF elevated at
presentation are decreased, which also parallel reductions in
plasma and CSF neurotoxicity. These data serve to support the
notion thatHAND is a reversiblemetabolic encephalopathy (Gen-
delman et al., 1998). Overall, ART has decreased the incidence of
HAD along with reductions in more common opportunistic infec-
tion and other AIDS-related illnesses.
Despite the increased improvement in HAD, thought due to
lower systemic viral loads, the lack of ART penetration into the
CNS still allows continued viral replication within the CNS (Leten-
dre et al., 2008). This may be mitigated by the administration of
CSF penetrating drugs directed to control CNS viral replication,
although the importance of CSF penetration has not been clearly
established (Letendre et al., 2004). While this most likely will not
prevent development of HAND, it could potentially slow disease
progression by decreasing levels of viral proteins and secretory
products from HIV-1 infected activated macrophages. Most
antiretroviral drugs cannot traverse the BBB or are quickly ef-
fluxed via P-glycoproteins (P-gp) or other efflux transporters.
P-gp inhibitors have shown some success in animal models of
HIVE; blockade of the P-gp efflux transporter allows retention
of antiretroviral drugs in the CNS and permits increased bioavail-
ability and activity within the CNS (Spitzenberger et al., 2007).
Strategies like these allow therapeutic modalities, which would
otherwise never pass the BBB, to act at sites of uncontrolled viral
growth within the CNS. There is also the added benefit of pre-
venting further complications that are associated with direct
administration into the CNS.
However, it should be noted that a recent study (ACTG 736) on
HAND found that while ART regimens with good penetration led
to lower CSF viral loads, they were also associated with poorer
neurocognitive performance (Marra et al., 2009). While larger
prospective randomized clinical trials need to be performed,
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level version of HAD/HIVE; and in the now chronic condition of
HIV-1 infection, our knowledge of the direct and indirect effects
on the brain is evolving. In addition, the effects of chronic treat-
ment with ART on CNS function are unknown.
Adjunctive Therapies for neuroAIDS
Because HAND shares many symptoms with other neurodegen-
erative disorders, drugs that were previously used in other
diseases have more recently been investigated. For many years,
memantine, currently approved for use in the treatment of AD,
has been suggested for treatment of HAND due to its observed
ability to block gp120 and Tat-induced neurotoxicity (Gendel-
man, 2007; Holden et al., 1999; Nath et al., 2000). It acts as
a noncompetitive antagonist of NMDA receptors and also has
been found to increase levels of brain-derived neurotrophic
factor and to protect dopamine function (Meisner et al., 2008).
While memantine administration has proved to be safe, no differ-
ences in cognitive performance have been observed in HIV-1-
infected patients, despite positive changes seen by magnetic
resonance spectroscopy (Schifitto et al., 2007).
Copolymer-1 (Cop-1), a known immune modulator respon-
sible for decreasing TNF-a and IL-12 levels, has shown neuro-
protective capabilities in a murine model of HIVE, resulting in
decreased neuronal damage, astrogliosis, and microgliosis
(Gorantla et al., 2007a, 2008). Cop-1 acts directly on neurons,
providing protection through protein kinase Ca antiapoptotic
signaling (Liu et al., 2007). Sodium valproate has been adminis-
tered in clinical trials during early-stage infection and appears to
bemildly beneficial in recovery fromHAND (Schifitto et al., 2006).
While not affecting viral replication, it supports modest improve-
ment in cognitive function (Schifitto et al., 2006); however, future
studies are necessary to determine the extent of improvement
possible with long-term administration.
Glycogen synthase kinase-3b (GSK-3b) is activated by Tat and
platelet activating factors and controls apoptosis through inhibi-
tion ofNF-kB (Schifitto et al., 2009). GSK-3b is inhibited by lithium
and provides an impetus to study GSK-3b inhibitors for HAND
(Dou et al., 2004; Gendelman, 2007; Schifitto et al., 2009). A pilot
study to test the effects of lithium on HAND showed improved
neuropsychological performance in ART-treated, neurologically
impaired individuals (Letendre et al., 2006). Further clinical trials
for this and other GSK-3b inhibitors need to be pursued to estab-
lish the nature of lithium effects on HAND (Crews et al., 2009).
Growth factors affect neuronal survival. Platelet-derived
growth factor (PDGF) is one such factor known toprotect neurons
from HIV-1-induced cytotoxicity (Peng et al., 2008a). PDGF
downregulates Bcl-2-associated Bax protein, an apoptosis-
inducing protein, and inhibits HIV-1gp120-induced cytochrome
c release (Peng et al., 2008b). These and other trials of adjunctive
therapies are necessary, as antiretroviral drugs alone have failed
to eliminate HAND in HIV-1 patients (Cysique and Brew, 2009).
Recentstudieshaveexamined theabilityofminocycline, ananti-
biotic with potent anti-inflammatory and neuroprotective proper-
ties, to protect against SIV encephalitis and neurodegeneration.
Minocycline-treated macaques had less severe encephalitis with
reduced brain expression of neuroinflammatory markers of p38
mitogen-activated protein kinase activation and MCP-1, as well
as reduced axonal degeneration and CNS virus replication (Zinket al., 2005). The findings have led to ongoing clinical studies
nowoperative in resource-limitedsettingsand in theUnitedStates.
All together, adjunctive therapies that have been shown to
be successful in the management of other neurodegenerative
disorders need also to be assessed in HAND for their efficacy
beyond the mere control of viral load. The therapeutic solution
relies on the means to harness the immune system for thera-
peutic benefit rather than simple control of viral replication. It is
for this reason that working to understand intercellular communi-
cation among different encephalic cells during infection is a vital
part in prospective HAND therapies.
Nanomedicine and CNS Drug Delivery
Abroad range of nanomedicines are being developed to improve
drug delivery for CNS disorders. These nanoformulations are de-
signed to circumvent the BBB (Gendelman et al., 2008). BBB
penetrance is dependent on nanoparticle size, shape, and
protein and lipid coatings. These all affect drug uptake, release,
and ingress across the barrier. The BBB poses limitations on
antiretroviral therapies and their pharmacokinetic and biodistri-
bution properties. Recent reports support the notion that nano-
technology can serve to improve the delivery of antiretroviral
medicines, called nanoART, across the BBB and affect biodistri-
bution and clinical benefit for HIV-1 disease (Nowacek and
Gendelman, 2009). To test CNS-penetrating ART, cell-based
nanoparticle delivery systems were developed in an effort to
transport ART across the BBB. Taking advantage of the Trojan
Horse principle, these nanoparticles are taken up by monocytes
and sheltered within the monocytes as they are carried across
the BBB. The drug is then released to act within the CNS
(Dou et al., 2006, 2009). Other laboratories have conjugated
nanoparticles with Tat, which has an affinity for nuclear transport
mechanisms (Berry et al., 2007). This results in a nanoparticle
that has high CNS penetrability while still bypassing efflux
transporters to prolong exposure within the CNS.
Animal Models for HIV-1 Neuropathogenesis
A specific challenge in finding ways to test new therapeutics for
HAND is the inability of HIV-1 to infect other species. The most
studiedmeans to address this is through theSIVmodel for neuro-
AIDS. SIV has many parallels to HIV-1, and therefore, infection of
monkeys provides a nonhuman primate model for researching
HIV-1 infection and HAND/HAD/HIVE. To examine the affects of
HIV-1 genes in vivo, portions of HIV-1 can be inserted into SIV,
creating hybrid simian-human immunodeficiency virus (SHIV).
There are many recent reviews of SIV and SHIV models for HIV-
1 neuropathogenesis (Clements et al., 2008; Crews et al., 2008;
Fox, 2008;Williams et al., 2008).Most studies focus on the devel-
opment of terminal disease with SIV encephalitis, and much has
been learned about its development and pathology, including its
in-depth molecular characterization (Roberts et al., 2003).
Several studies have recently examined the brains of SIV-
infectedmonkeys during chronic infection and during the admin-
istration of effective ART, in the absence of the confounding
conditions and experimental limitations that exist in humans. In
chronic SIV infection (animals infected for 2 years but with no
obvious disease), evidence of an active viral-host interaction
with both virus and CD8+ T cells present in the brain andNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 139
Neuron
Reviewincreased expression of a number of immune modulatory mole-
cules (Roberts et al., 2006). Two studies have examined the
effects of combination antiretroviral treatment. In one, markers
of CNS inflammation were reduced, but viral DNA persisted in
the brain, indicating the possibility of the brain remaining a reser-
voir for the virus (Clements et al., 2005). In the other, treatment
reduced viral RNA in the brain and prevented the development
of SIV-induced neurophysiological abnormalities but did not
affect the number of CD8+ T cell in the brain; and varied effects
were seen on production of immunemodulatorymolecules (Mar-
condes et al., 2009). Clearly, given the current clinical state,
further study of the chronically infected brain in the presence
of treatment is needed to understand the substrates of HAND.
However, the expense of this system and limitations in use
have led to the development of model systems that use HIV-1
in ‘‘humanized’’ animal models. For example, such ‘‘humanized’’
mice have been developed through reconstituting irradiated
BALB/c-Rag2/gc
/ mice with umbilical cord blood-derived
CD34+ hematopoietic stem cells (Gorantla et al., 2007b). Direct
injection of HIV-1-infected monocyte-derived macrophages
(MDM) intracerebrally induces HIVE, providing a good model to
study therapeutics that target HIVE. Other humanized rodent
models, such as those with transplanted human bone marrow,
liver, and thymus, have been used for studies on HIV-1 preven-
tion and pathogenesis (Wege et al., 2008) but not yet for HIV neu-
ropathogenesis. The application of these and other rodent
models to current issues in HAND, including its chronicity, will
be a useful addition to our research resources.
Drug Abuse and NeuroAIDS
Drug users represent a significant proportion of theHIV-1 infected
and at risk population. The influence of concurrent drug abuse in
HIV neuropathogenesis is alsoquite is significant.Neuropatholog-
ically, drug abusers show greater levels of neuroinflammation, as
evidencedbymicroglial activation,astrocytosis, andCD8 lympho-
cytic brain infiltration (Anthony et al., 2005; Tomlinson et al., 1999).
Alcohol, marijuana, nitrite inhalants, amphetamines, opiates,
cocaine, and hallucinogens are the drugsmost commonly associ-
ated with HIV-1. These have been the subjects of many reviews in
recent years (Anthony and Bell, 2008; Nath et al., 2008).
Morphine is a well-known opioid analgesic used extensively
in clinical practice with significant dampening effects on the
immune system (Roy et al., 2001, 2006). Studies in rhesus
macaques that were chronically administered opioids have
yielded conflicting results on the effects of morphine on SIV
pathogenesis (Donahoe et al., 2009; Kumar et al., 2006).
Cocaine has been one of themost widely abused drugs world-
wide. Epidemiological studies on abused drugs and AIDS link
abuse of cocaine (by different routes) to increased incidence of
HIV-1 seroprevalence and progression to AIDS (Baldwin et al.,
1997). In laboratory studies, cocaine exposure has been shown
to aggravate neurotoxic effects of HIV-1 proteins Tat and gp120,
thus mediating accelerated neuronal apoptosis (Aksenov et al.,
2006; Turchan-Cholewo et al., 2006).
Cocaine has multiple immunomodulatory effects, including the
ability to influence cytokine release in immunoeffector cells.
Cocaine was reported to increase the production of p24 in HIV-
1-infected leukocytes by a mechanism involving TGF-b (Peterson140 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.et al., 1990; Pettoello-Mantovani et al., 1998). The interaction
between cocaine and HIV-1 has also been evaluated in vivo using
ahybrid-mousemodel (huPBLSCIDmouse) infectedwithHIV-1, in
which cocaineadministrationdecreasesCD4+cells and increases
circulating virus loads (Roth et al., 2002). In addition, cocaine is
known toenhance the secretionofMCP-1 inbrain endothelial cells
(Zhang et al., 1998), thereby facilitating increased influx of infected
cells across the BBB (Dhillon et al., 2008). These findings under-
score the role of cocaine as a cofactor for neuroAIDS.
HIV-infected individuals who are dependent on methamphet-
amine (METH) have a higher rate of neuropsychological impair-
ment than those who do not use the drug (Rippeth et al., 2004).
HIV-1-infectedMETHusers onART alsomanifest a higher plasma
viral load than infected individuals onARTwhoarenot usingMETH
(Cadet et al., 2003; Langford et al., 2003). METH administration is
known to result in long-lasting dopamine depletion in humans and
animals (Davidson et al., 2001). Intriguingly, there is evidence of
dopaminergic dysfunction in neuroAIDS (Kumar et al., 2009),
leading to thepossibility of interactionwith thedopamine-affecting
drugs cocaine andMETH. Neuropathological examinations of the
brains ofMETHuserswithHIVE revealeda higher degreeof lossof
calbindin interneurons in theneocortex and increasedmicrogliosis
(Chanaetal., 2006). Lossofsuch interneurons, includingparvalbu-
min interneurons, correlated well with memory abnormalities in
METH users with HIV-1 (Langford et al., 2003). Interestingly, tran-
scriptional profiling studies revealed that in thebrainsof thosewith
HIVE, METH users had significantly increased expression of
a group of IFN-inducible genes (Everall et al., 2005).
Conclusions
HIV-1 commonly induces a spectrum of neurologic disorders that
include opportunistic infections caused as a consequence of
immunecompromiseand those resulting fromdirect virus-associ-
ated damage to the nervous system. These are common and
debilitating and continue to occur despite usage of ART. Interest-
ingly, neurologic disease parallels disordered regulation of both
the innate and adaptive immunity and is driven through cell cross-
talk that includes glial-neuronal interactions. Viral and cellular
mediators linked to MP activation, growth factors, and adaptive
immune surveillance that includes cytotoxic and regulatory
T cells underlie disease pathogenesis. The control of antiretroviral
andneuroprotectiveT cell functions andmacrophagepolarization
are essential in combating the clinical consequences of HAND.
Understanding the causes of neurodegeneration during HIV-1
infection and the parameters whereby certain individuals develop
disease can provide researches with new therapeutic targets to
positively affect diseaseoutcomes.New insights into immunoreg-
ulation,drugcarriage,neuroprotectivestrategies,and intercellular
communications will certainly lead to improved mental health
outcomes by facilitating drug access to the CNS and control of
pathologicevents.Moreover, studiesofneural immuneprocesses
in the setting of neuroAIDS will also provide novel ideas of broad
implication to a range of neurodegenerative diseases.
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